Volume 14, Number 5—May 2008
Perspective
Scale-up of Multidrug-Resistant Tuberculosis Laboratory Services, Peru
Sonya S. Shin*
, Martin Yagui†, Luis Ascencios†, Gloria Yale‡, Carmen Suarez‡, Neyda Quispe†, Cesar Bonilla‡, Joaquin Blaya§, Allison Taylor¶, Carmen Contreras#, and Peter Cegielski¶
, Martin Yagui†, Luis Ascencios†, Gloria Yale‡, Carmen Suarez‡, Neyda Quispe†, Cesar Bonilla‡, Joaquin Blaya§, Allison Taylor¶, Carmen Contreras#, and Peter Cegielski¶
Table 4
Considerations for decentralized drug susceptibility testing (DST) capacity for first-line drugs, Peru
| Criterion | Ideal situation |
|---|---|
| Drugs to test | First-line DST; isoniazid and rifampin most important because empiric treatment regimen and further DST may follow |
| Reproducibility | Because drug-resistant samples identified by regional DST, then referred to National Reference Laboratory for DST to second-line drugs, sensitivity most important |
| Sample source | Direct method optimal for processing at local health clinic to minimize turnaround time |
| Cost per sample | Low cost |
| Time to obtain result | Rapid |
| Technical demand | Less technically demanding, less processing time |
| Biologic safety risk | Low biosecurity risk |
| Required equipment | Limited additional equipment (refridgerated centrifuge) procured and maintained in local site |
| Reagents and supplies | Commonly used reagents and supplies available through local vendors is preferable |
Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.